Abstracts tagged "spine"

Abstract Number: 0904 • ACR Convergence 2021
Data-driven Definitions Based on Inflammatory Lesions for a Positive MRI of the Spine Consistent with Axial Spondyloarthritis
Walter Maksymowych¹, Robert Lambert², Xenofon Baraliakos³, Susanne Pedersen⁴, Iris Eshed⁵, Ulrich Weber⁶, Pedro Machado⁷, Manouk de Hooge⁸, Joachim Sieper⁹, Stephanie Wichuk², Denis Poddubnyy¹⁰, Martin Rudwaleit¹¹, Robert Landewé¹², Désirée van der Heijde¹³ and Mikkel Ostergaard¹⁴, ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁴Rigshospitalet, Center for Arthritis Research, Glostrup, Denmark, ⁵Sheba Medical Center, Ramat Gan, Israel, ⁶Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁸Ghent University Hospital, Ghent, Belgium, ⁹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ¹⁰Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ¹¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ¹²Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ¹³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: The ASAS definition of a positive MRI for inflammation in the spine (ASAS-MRI+) is intended for classification of patients as having axSpA but is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].